Online inquiry

IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9642MR)

This product GTTS-WQ9642MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 608
UniProt ID P07766; Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9642MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ150MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ11767MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ3595MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ13054MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ10770MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ7987MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GX-H9
GTTS-WQ3980MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ13215MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05082566
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW